SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1440)4/15/2003 5:50:55 PM
From: Icebrg  Read Replies (2) of 3044
 
There were problems with the webcasted CC today. Very poor sound quality and after a while the transmission was completely cut off.

Anyhow, before the transmission ended, I noted that they mentioned that they are planning to highlight MLN02 data in IBD at a conference in May.

There has been doubts with regard to this agent due to a perceived lack of good results and PR-based enthusiasm following the conclusion of the phase II trial in the Crohn's disease indication.

If however MLNM think it is worthwhile to mention a future conference presentation of the IBD-data, one (or at least I) cannot but assume, that the data are at least good enough to warrant a continuation into phase III. (Where DNA will meet the development costs).

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News